Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 1.27B 1.12B 1.05B 956M 1.8B 122B 1.82B 12.7B 4.92B 62.17B 4.75B 4.65B 200B P/E 2026 *
-8.02x
P/E 2027 * -7.16x
Enterprise Value 1.27B 1.12B 1.05B 956M 1.8B 122B 1.82B 12.7B 4.92B 62.17B 4.75B 4.65B 200B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day-2.52%
1 week-7.26%
Current month-9.39%
1 month-7.04%
3 months+4.85%
6 months+37.29%
Current year+49.21%
1 week 12.16
Extreme 12.165
14.12
1 month 11.86
Extreme 11.86
14.12
Current year 7.23
Extreme 7.23
14.68
1 year 7.23
Extreme 7.23
14.93
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
20.91
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2018
Director of Finance/CFO 52 31/08/2019
Chief Tech/Sci/R&D Officer - 17/08/2025
Director TitleAgeSince
Chairman 68 06/03/2018
Director/Board Member 47 06/05/2018
Director/Board Member 62 31/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/09/26 Exercice

Chief Financial Officer

40,200 0.0388%
24/09/26 Exercice

Chief Financial Officer

1,800 0.0017%
26/08/26 Exercice

Chief Financial Officer

231,000 0.2232%
Change 5-day change 1-year change 3-year change Capi.($)
-2.52%-7.26%+7.82%+107.22% 1.27B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -0.45%-1.26%+49.73%+118.97% 39.18B
Weighted average by Cap. +0.11%-0.86%+58.60%+129.83%

Financials

2026 *2027 *
Net sales - -
Net income -167M -148M -138M -126M -237M -16.01B -240M -1.67B -648M -8.19B -625M -612M -26.27B -200M -178M -166M -151M -286M -19.25B -288M -2.01B -779M -9.84B -752M -736M -31.59B
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
111
Date Price Change Volume
02/10/26 US$12.21 -2.52% 1,232,084
01/10/26 US$12.52 -7.05% 1,770,890
30/09/26 US$13.47 +0.75% 1,961,192
29/09/26 US$13.37 +0.75% 977,262
28/09/26 US$13.27 +0.84% 1,515,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
12.20USD
Average target price
21.08USD
Spread / Average Target
+72.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ORIC Stock